These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 35729775)
1. Examining the Role of the Linker in Bitopic Awalt JK; Nguyen ATN; Fyfe TJ; Thai BS; White PJ; Christopoulos A; Jörg M; May LT; Scammells PJ J Med Chem; 2022 Jul; 65(13):9076-9095. PubMed ID: 35729775 [TBL] [Abstract][Full Text] [Related]
2. A Structure-Activity Relationship Study of Bitopic N Aurelio L; Baltos JA; Ford L; Nguyen ATN; Jörg M; Devine SM; Valant C; White PJ; Christopoulos A; May LT; Scammells PJ J Med Chem; 2018 Mar; 61(5):2087-2103. PubMed ID: 29446948 [TBL] [Abstract][Full Text] [Related]
3. The effect of two selective A Cooper SL; March J; Sabbatini AR; Hill SJ; Jörg M; Scammells PJ; Woolard J Br J Pharmacol; 2020 Jan; 177(2):346-359. PubMed ID: 31596949 [TBL] [Abstract][Full Text] [Related]
4. Failure of CGS15943A to block the hypotensive action of agonists acting at the adenosine A3 receptor. Patel M; Sheehan MJ; Strong P Br J Pharmacol; 1994 Nov; 113(3):741-8. PubMed ID: 7858863 [TBL] [Abstract][Full Text] [Related]
5. Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes. Safran N; Shneyvays V; Balas N; Jacobson KA; Nawrath H; Shainberg A Mol Cell Biochem; 2001 Jan; 217(1-2):143-52. PubMed ID: 11269659 [TBL] [Abstract][Full Text] [Related]
6. 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors. van Tilburg EW; van der Klein PA; von Frijtag Drabbe Künzel J; de Groote M; Stannek C; Lorenzen A; IJzerman AP J Med Chem; 2001 Aug; 44(18):2966-75. PubMed ID: 11520205 [TBL] [Abstract][Full Text] [Related]
7. Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery. Baltos JA; Gregory KJ; White PJ; Sexton PM; Christopoulos A; May LT Biochem Pharmacol; 2016 Jan; 99():101-12. PubMed ID: 26581123 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Rueda P; Merlin J; Chimenti S; Feletou M; Paysant J; White PJ; Christopoulos A; Sexton PM; Summers RJ; Charman WN; May LT; Langmead CJ Front Pharmacol; 2021; 12():628060. PubMed ID: 33776771 [TBL] [Abstract][Full Text] [Related]
9. Exploring the Role of N Petrelli R; Scortichini M; Kachler S; Boccella S; Cerchia C; Torquati I; Del Bello F; Salvemini D; Novellino E; Luongo L; Maione S; Jacobson KA; Lavecchia A; Klotz KN; Cappellacci L J Med Chem; 2017 May; 60(10):4327-4341. PubMed ID: 28447789 [TBL] [Abstract][Full Text] [Related]
10. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Valant C; May LT; Aurelio L; Chuo CH; White PJ; Baltos JA; Sexton PM; Scammells PJ; Christopoulos A Proc Natl Acad Sci U S A; 2014 Mar; 111(12):4614-9. PubMed ID: 24619092 [TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Adenosine Receptor Agonists That Exhibit Subtype Selectivity. Knight A; Hemmings JL; Winfield I; Leuenberger M; Frattini E; Frenguelli BG; Dowell SJ; Lochner M; Ladds G J Med Chem; 2016 Feb; 59(3):947-64. PubMed ID: 26756468 [TBL] [Abstract][Full Text] [Related]
12. 5'-C-Ethyl-tetrazolyl-N(6)-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists. Petrelli R; Torquati I; Kachler S; Luongo L; Maione S; Franchetti P; Grifantini M; Novellino E; Lavecchia A; Klotz KN; Cappellacci L J Med Chem; 2015 Mar; 58(5):2560-6. PubMed ID: 25699637 [TBL] [Abstract][Full Text] [Related]
13. Substituted 4-phenylthiazoles: Development of potent and selective A Abdelrahman A; Yerande SG; Namasivayam V; Klapschinski TA; Alnouri MW; El-Tayeb A; Müller CE Eur J Med Chem; 2020 Jan; 186():111879. PubMed ID: 31780082 [TBL] [Abstract][Full Text] [Related]
14. A physiological role of the adenosine A3 receptor: sustained cardioprotection. Liang BT; Jacobson KA Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6995-9. PubMed ID: 9618527 [TBL] [Abstract][Full Text] [Related]
15. VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Chuo CH; Devine SM; Scammells PJ; Krum H; Christopoulos A; May LT; White PJ; Wang BH Clin Exp Pharmacol Physiol; 2016 Oct; 43(10):976-82. PubMed ID: 27377874 [TBL] [Abstract][Full Text] [Related]
16. Adenosine A3 agonist cardioprotection in isolated rat and rabbit hearts is blocked by the A1 antagonist DPCPX. Kilpatrick EL; Narayan P; Mentzer RM; Lasley RD Am J Physiol Heart Circ Physiol; 2001 Aug; 281(2):H847-53. PubMed ID: 11454590 [TBL] [Abstract][Full Text] [Related]
17. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. Jacobson KA; Xie R; Young L; Chang L; Liang BT J Biol Chem; 2000 Sep; 275(39):30272-9. PubMed ID: 10887176 [TBL] [Abstract][Full Text] [Related]
18. Stimulation of the adenosine A3 receptor, not the A1 or A2 receptors, promote neurite outgrowth of retinal ganglion cells. Nakashima KI; Iwao K; Inoue T; Haga A; Tsutsumi T; Mochita MI; Fujimoto T; Tanihara H Exp Eye Res; 2018 May; 170():160-168. PubMed ID: 29486164 [TBL] [Abstract][Full Text] [Related]
19. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. Dana A; Baxter GF; Walker JM; Yellon DM J Am Coll Cardiol; 1998 Apr; 31(5):1142-9. PubMed ID: 9562020 [TBL] [Abstract][Full Text] [Related]
20. Heteromeric association creates a P2Y-like adenosine receptor. Yoshioka K; Saitoh O; Nakata H Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7617-22. PubMed ID: 11390975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]